Linzagolix (choline)
Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids[1].
Product Specifications
CAS Number
1321816-57-2
Product Name Alternative
KLH-2109 (choline) ; OBE-2109 (choline)
UNSPSC
12352005
Target
GnRH Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/linzagolix-choline.html
Smiles
OCC[N+](C)(C)C.O=C([O-])C1=C(C(NC2=O)=CS1)C(N2C3=CC(OCC4=C(C=CC(F)=C4F)OC)=C(C=C3F)OC)=O
Molecular Formula
C27H28F3N3O8S
Molecular Weight
611.59
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
